In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Teva becomes European generics leader via ratiopharm takeover

Executive Summary

Following several months of rumored offers from the likes of Pfizer and Actavis, Teva Pharmaceutical Industries has managed to sign a definitive agreement to acquire ratiopharm, a top private generic drug maker, for €3.625bn ($4.989bn), which includes the assumption of €600mm in debt. Ratiopharm is owned by VEM Holding, an asset management company controlled by the Merckle family.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register